EGI
ARCT icon

EAM Global Investors’s Arcturus Therapeutics ARCT Stock Holding History

EAM Global Investors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,948
Closed -$1.45M – 133
2020
Q2 		$1.45M Buy
+30,948
New +$1.07M 0.65% 77

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EAM Global Investors's ARCT Position: Q3 2020 in Review

EAM Global Investors sold out of Arcturus Therapeutics (ARCT) in Q3 2020, closing a stake of 30,948 shares — an estimated $1.45M sold.

EAM Global Investors first reported a position in ARCT in Q2 2020 and held it in 1 quarter. The position peaked at $1.45M in Q2 2020. 127 funds tracked by Wall St. Rank hold ARCT as of Q3 2020.

  • EAM Global Investors reported no remaining Arcturus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • EAM Global Investors sold 30,948 Arcturus Therapeutics shares in Q3 2020, an estimated $1.45M.
  • EAM Global Investors first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 1 quarter.
  • EAM Global Investors's Arcturus Therapeutics position peaked at $1.45M in Q2 2020.
  • 127 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2020.

Based on EAM Global Investors's 13F filing for Q3 2020, filed 13 Nov 2020.